Product Type
Condition
Binding
Collectible Attributes
Free Shipping
Seller Location
Seller Rating
Published by Springer, 2013
ISBN 10: 3642252397ISBN 13: 9783642252396
Seller: Anybook.com, Lincoln, United Kingdom
Book
Condition: Good. Volumes 1 and 2. This is an ex-library book and may have the usual library/used-book markings inside.This book has hardback covers. Clean from markings. In good all round condition. Please note the Image in this listing is a stock photo and may not match the covers of the actual item,3450grams, ISBN:9783642252396.
Published by Springer, 2006
Seller: Antiquariat Thomas Haker GmbH & Co. KG, Berlin, Germany
Association Member: GIAQ
Book
Hardcover/Pappeinband. 920 p. Very good. Shrink wrapped. / Sehr guter Zustand. In Folie verschweißt. Sprache: Englisch Gewicht in Gramm: 2204.
Published by Springer, Berlin, 2006
ISBN 10: 3540256385ISBN 13: 9783540256380
Seller: Research Ink, Takoma Park, MD, U.S.A.
Book
Hardback. Condition: Very Good. xxxi + 889 pp. Springer Reference. Rubber-stamped on front free endpaper. book.
Published by Springer, 2006
ISBN 10: 3540256385ISBN 13: 9783540256380
Book
Couverture rigide. Condition: bon. R160226211: 2006. In-4. Relié. Bon état, Couv. convenable, Dos satisfaisant, Intérieur frais. XXXI + 889 pages - ouvrage en anglais - texte sur deux colonnes. . . . Classification Dewey : 420-Langue anglaise. Anglo-saxon.
Published by SP SPRINGER, 2006
ISBN 10: 3540256385ISBN 13: 9783540256380
Seller: Universal Store, Princeton Junction, NJ, U.S.A.
Book
Condition: Brand New. Brand New! Fast Delivery , Delivery with in 6-9 working Day Only , Original Edition. Excellent Quality, Printing In English Language, Quick delivery by FEDEX & DHL. Our courier service is not available at PO BOX& APO BOX.
Published by Springer, 2013
ISBN 10: 3642252397ISBN 13: 9783642252396
Seller: Basi6 International, Irving, TX, U.S.A.
Book
Condition: Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service.
Published by SP SPRINGER, 2006
ISBN 10: 3540256385ISBN 13: 9783540256380
Seller: Universal Store, Princeton Junction, NJ, U.S.A.
Book
Condition: Brand New. Brand New! Fast Delivery , Delivery with in 6-9 working Day Only , Original Edition. Excellent Quality, Printing In English Language, Quick delivery by FEDEX & DHL. Our courier service is not available at PO BOX& APO BOX.
Published by Springer Berlin Heidelberg, 2013
ISBN 10: 3642252397ISBN 13: 9783642252396
Seller: Buchpark, Trebbin, Germany
Book
Condition: Sehr gut. Zustand: Sehr gut - Buchschnitt verkürzt- gepflegter, sauberer Zustand - Ausgabejahr 2013 | Seiten: 1452 | Sprache: Englisch.
Published by Springer Berlin Heidelberg, 2013
ISBN 10: 3642252397ISBN 13: 9783642252396
Seller: moluna, Greven, Germany
Book Print on Demand
Condition: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. A landmark in the continuously changing world of drugsEssential reading for scientists and managers in the pharmaceutical industry involved in drug finding, drug development and decision making in the development processOf use for governmen.
Published by Springer Berlin Heidelberg Feb 2013, 2013
ISBN 10: 3642252397ISBN 13: 9783642252396
Seller: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Germany
Book Print on Demand
Buch. Condition: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Safety aspects have become an outstanding issue in the process of drug discovery and development. Until 15 years ago safety aspects were addressed by pharmacological testing of the selected compound in high doses in tests directed at indications other than the intended indication of the new compound. These tests were followed by pharmacokinetic studies, which were mainly aimed at confirming of a suitable half-life time and at oral activity. Safety aspects relied mostly on toxicity studies, which however gave information on changes of organ structure rather than on organ function. Toxicological and pharmacokinetic studies were adapted to the progress of studies in clinical pharmacology and clinical trails. But the success rate in the pharmaceutical industry and the introduction of new chemical entities to the market per year dropped dramatically, whereas the development time for a new compound increased, sometimes exceeding the patent protection. A change of strategy was therefore adopted, involving the following changes: - Parallel instead of sequential involvement of the various disciplines (multidimensional compound optimization).- The term 'Safety Pharmacology' was coined. The International Conference on Harmonization (ICH) founded a Safety Pharmacology Working Group. Easily accessible and the most informative tests now have to be selected.- Exposure of a drug to the body by pharmacokinetic studies on absorption, distribution, metabolism and excretion has to be investigated at an early stage of development and can contribute to the selection of a compound for development. Toxicology experienced major achievements by the introduction of new methods, e.g., in silico methods, toxicogenomics and toxicoproteomics.The book is a landmark in the continuously changing world of drugs. As such it is important reading for many groups: not only for all students of pharmacology and toxicology but also for physicians, especially those involved in clinical trials of drugs, and for pharmacists who have to know the safety requirements of drugs.The book is absolutely essential for scientists and managers in the pharmaceutical industry who are involved in drug finding, drug development and decision making in the development process.In particular, the book will be of use for government institutions and committees working on official guidelines for drug evaluation worldwide. 1452 pp. Englisch.
Published by Springer Berlin Heidelberg, 2013
ISBN 10: 3642252397ISBN 13: 9783642252396
Seller: AHA-BUCH GmbH, Einbeck, Germany
Book
Buch. Condition: Neu. Druck auf Anfrage Neuware - Printed after ordering - Safety aspects have become an outstanding issue in the process of drug discovery and development. Until 15 years ago safety aspects were addressed by pharmacological testing of the selected compound in high doses in tests directed at indications other than the intended indication of the new compound. These tests were followed by pharmacokinetic studies, which were mainly aimed at confirming of a suitable half-life time and at oral activity. Safety aspects relied mostly on toxicity studies, which however gave information on changes of organ structure rather than on organ function. Toxicological and pharmacokinetic studies were adapted to the progress of studies in clinical pharmacology and clinical trails. But the success rate in the pharmaceutical industry and the introduction of new chemical entities to the market per year dropped dramatically, whereas the development time for a new compound increased, sometimes exceeding the patent protection. A change of strategy was therefore adopted, involving the following changes: - Parallel instead of sequential involvement of the various disciplines (multidimensional compound optimization).- The term 'Safety Pharmacology' was coined. The International Conference on Harmonization (ICH) founded a Safety Pharmacology Working Group. Easily accessible and the most informative tests now have to be selected.- Exposure of a drug to the body by pharmacokinetic studies on absorption, distribution, metabolism and excretion has to be investigated at an early stage of development and can contribute to the selection of a compound for development. Toxicology experienced major achievements by the introduction of new methods, e.g., in silico methods, toxicogenomics and toxicoproteomics.The book is a landmark in the continuously changing world of drugs. As such it is important reading for many groups: not only for all students of pharmacology and toxicology but also for physicians, especially those involved in clinical trials of drugs, and for pharmacists who have to know the safety requirements of drugs.The book is absolutely essential for scientists and managers in the pharmaceutical industry who are involved in drug finding, drug development and decision making in the development process.In particular, the book will be of use for government institutions and committees working on official guidelines for drug evaluation worldwide.
Published by Springer, 2013
ISBN 10: 3642252397ISBN 13: 9783642252396
Seller: Mispah books, Redhill, SURRE, United Kingdom
Book
Hardcover. Condition: Like New. Like New. book.
Published by Springer, 2013
ISBN 10: 3642252397ISBN 13: 9783642252396
Seller: GF Books, Inc., Hawthorne, CA, U.S.A.
Book
Condition: New. Book is in NEW condition. 2.31.
Published by Springer, 2013
ISBN 10: 3642252397ISBN 13: 9783642252396
Seller: Book Deals, Tucson, AZ, U.S.A.
Book
Condition: New. New! This book is in the same immaculate condition as when it was published 2.31.
Published by Springer, 2013
ISBN 10: 3642252397ISBN 13: 9783642252396
Seller: GF Books, Inc., Hawthorne, CA, U.S.A.
Book
Condition: Good. Book is in Used-Good condition. Pages and cover are clean and intact. Used items may not include supplementary materials such as CDs or access codes. May show signs of minor shelf wear and contain limited notes and highlighting. 2.31.
Published by Springer, 2013
ISBN 10: 3642252397ISBN 13: 9783642252396
Seller: GF Books, Inc., Hawthorne, CA, U.S.A.
Book
Condition: Fine. Book is in Used-LikeNew condition. Pages and cover are clean and intact. Used items may not include supplementary materials such as CDs or access codes. May show signs of minor shelf wear. 2.31.
Published by Springer, 2013
ISBN 10: 3642252397ISBN 13: 9783642252396
Seller: GF Books, Inc., Hawthorne, CA, U.S.A.
Book
Condition: Very Good. Book is in Used-VeryGood condition. Pages and cover are clean and intact. Used items may not include supplementary materials such as CDs or access codes. May show signs of minor shelf wear and contain very limited notes and highlighting. 2.31.